Inhibikase Therapeutics (IKT) Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Press/Media

Period	13 Jun 2022

Media coverage

Title	Inhibikase Therapeutics (IKT) Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
Media name/outlet	Street Insider
Country/Territory	United States
Date	13/06/22
URL	https://www.streetinsider.com/Corporate+News/Inhibikase+Therapeutics+%28IKT%29+Announces+Advancement+of+IkT-148009+Phase+2+%27201%27+Program+Following+FDA+Review/20205307.html
Persons	C. Olanow